Compositions and methods comprising histidyl-trna synthetase splice variants having non-canonical biological activities
AssigneesaTyr Pharma, Inc., Pangu BioPharma Limited
InventorsJie Zhou, Ching-Fun Lau, Zhiwen Xu, Wing-Sze Lo, Kristi Helen Piehl, Leslie Ann Greene
Life of this patent
Estimating the term…
Abstract
Isolated histidyl-tRNA synthetase splice variant polynucleotides and polypeptides having non-canonical biological activities are provided, as well as compositions and methods related thereto.
Claims18
1-49. (canceled)
A synthetic polynucleotide selected from (a) a polynucleotide that specifically hybridizes to a splice junction that is unique to a histidyl-tRNA synthetase (HRS) polynucleotide selected from SEQ ID NO:5, 8, and 10;
- and (b) a polynucleotide that encodes a HRS splice variant polypeptide of SEQ ID NO:6, 9, or 11 or a variant thereof having at least 95% identity along its length to SEQ ID NO:6, 9, or 11.
A recombinant vector, comprising a polynucleotide selected from (a) a polynucleotide that specifically hybridizes to a splice junction that is unique to a histidyl-tRNA synthetase (HRS) polynucleotide selected from SEQ ID NO:5, 8, and 10;
- and (b) a polynucleotide that encodes a HRS splice variant polypeptide of SEQ ID NO:6, 9, or 11 or a variant thereof having at least 95% identity along its length to SEQ ID NO:6, 9, or 11, wherein the polynucleotide is operably linked to a transcriptional regulatory element.
Dependencies are inferred from the claim text.